Huntington’s disease research news. In plain language. Written by scientists. For the global HD community.
Jeff Carroll and Ed Wild present EuroBuzz episode 2 - bringing the European HD Network Meeting direct to you, in plain language. Watch online!
Our second daily report from the European Huntington’s Disease Network 2012 Meeting in Stockholm. Video of both EuroBuzz evening sessions will be available to watch on HDBuzz.net next week.
Drugs called anti-sense oligonucleotides, or ASOs, are one way of silencing the gene that causes Huntington's disease. A new publication in the journal Neuron suggests that ASO gene silencing reaches further in the brain than other methods, lasts longer and is safe.
A study in yeast has highlighted a DNA-reading protein called SPT4 as possibly controlling which CAG-containing genes are active. Since Huntington's disease is caused by a gene with a long CAG stretch, this might be important for understanding how the HD gene works.
Our second daily report from the annual Huntington's Disease Therapeutics Conference in Palm Springs, California. The second day's sessions focused on gene silencing. You can tweet @HDBuzzFeed or email firstname.lastname@example.org with your questions, comments and queries.
Most HD researchers are pretty excited by the idea of 'silencing' the Huntington's disease gene, to reduce production of the harmful huntingtin protein. Two challenges - safety and delivery - are now closer to being solved thanks to collaborative work by academic and industry researchers.
Gene silencing drugs aim to slow down or prevent Huntington's disease by telling cells not to make the harmful protein. For the first time, a study has shown that gene silencing hits its target and is safe in the complex brains of rhesus monkeys.
A better understanding of the normal role of the huntingtin protein would make developing treatments easier. Surprising new results from French researchers suggest that huntingtin influences tiny hair-like structures called 'cilia'. Now we need to figure out what it means for patients.
Most Huntington's disease researchers agree silencing the huntingtin gene is one of the most promising treatments in the pipeline. But we don't know whether switching off the gene is safe. Now a Canadian team has shown that 'allele-specific' gene silencing - targeting just the mutant copy of the gene, and leaving the healthy copy active - works and is safe in an HD mouse.